Trial Profile
A Study of the Safety and Efficacy of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2022
Price :
$35
*
At a glance
- Drugs IMM 101 (Primary) ; Nivolumab (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immodulon Therapeutics
- 07 Jun 2022 Final results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 06 Apr 2022 Status changed from active, no longer recruiting to completed.
- 12 May 2021 Status changed from recruiting to active, no longer recruiting.